

## MYPT1 pSer554 (mouse; residues 547-618), pAb

Alternate Names: Protein Phosphatase 1, Regulatory Subunit 12A, PPP1R12A, Myosin Phosphate target subunit 1

Cat. No. 68-0045-100  
Lot. No. 30284

Quantity: 100 µg  
Storage: -20°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS

Page 1 of 2

This antibody was developed and validated by the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (University of Dundee, Dundee, UK).

### Background

Protein ubiquitylation and protein phosphorylation are the two major mechanisms that regulate the functions of proteins in eukaryotic cells. However, these different post-translational modifications do not operate independently of one another, but are frequently interlinked to enable biological processes to be controlled in a more complex and sophisticated manner. Studying how protein phosphorylation events control the ubiquitin system and how ubiquitylation regulates protein phosphorylation has become a focal point of the study of cell regulation and human disease. The mammalian MYPT family consists of the products of five genes, denoted MYPT1, MYPT2, MBS85, MYPT3 and TIMAP (Grassie *et al.*, 2011). Myosin phosphatase (MP) activity, which regulates smooth muscle relaxation, is regulated by the phosphorylation of its regulatory subunit, myosin phosphatase targeting subunit 1 (MYPT1) (Cheng *et al.*, 2013). Cloning of human MYPT1 was first described by Takahashi *et al.* (1997). An example of the interplay between phosphorylation, ubiquitylation, and methylation, has been highlighted in a recent study showing that MYPT1 can be methylated *in vitro* and *in vivo* by histone lysine methyltransferase SETD7 and demethylated by histone demethylase LSD1. LSD1 silencing increased MYPT1 protein levels, decreasing the steady state level of phosphorylated retinoblastoma 1 (RB1; Ser

### Physical Characteristics

**Quantity:** 100 µg

**Concentration:** to be provided on shipping

**Source:** sheep polyclonal antibody

**Immunogen:** mouse MYPT1 (residues 547-618) [STYHRST(pS)NRLWAEDS]

**Purification:** affinity-purified against phospho peptide

**Formulation:** phosphate-buffered saline

**Specificity:** detects MYPT1 at ~130 kDa

**Reactivity:** mouse; other species not tested


**Stability/Storage:** 12 months at -20°C; aliquot as required

### Research Applications and Quality Assurance

**Western Immunoblotting:** use 1 µg/ml; add 10 µg of the non-phosphorylated form of the peptide immunogen (Cat# 68-1006-001 provided) to your immunoblotting incubation per 1 µg of polyclonal antibody in order to

deplete any non-phospho specific polyclonal antibodies present.

**Immunoprecipitation:** not tested



#### Western Blotting Analysis:

Following the transfection of HEK293 cells with FLAG-tagged wild-type MYPT1 (MYPT1 wt) or a FLAG-tagged MYPT1 mutant (MYPT1 S554A), cells were lysed and immunoprecipitation was performed using a commercially available anti-FLAG antibody. Immunoprecipitation of untransfected HEK293 cell lysate (non transf) was also included as a control. Western blotting was subsequently performed probing with a commercially available anti-MYPT1 antibody or the anti-MYPT1 pSer554 antibody (Cat# 68-0045-100). A band was detected from the FLAG-tagged immunoprecipitate of the MYPT1 wt, and to a lesser extent the MYPT1 S554A mutant cell lysates when probed with 1.0 µg/ml of the anti MYPT1 pSer554 mouse polyclonal antibody (Cat# 68-0045-100). HEK293 cell lysate (293 lysate) was included in the Western blotting experiment as a control.

Continued on page 2



www.ubiquigent.com  
Dundee, Scotland, UK

#### ORDERS / SALES SUPPORT

International: +1-617-245-0020  
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)  
Email: sales.support@ubiquigent.com

#### UK HQ and TECHNICAL SUPPORT


International: +44 (0) 1382 381147 (9AM-5PM UTC)  
US/Canada: +1-617-245-0020 (9AM-5PM UTC)  
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0



## MYPT1 pSer554 (mouse; residues 547-618), pAb

**Alternate Names:** Protein Phosphatase 1, Regulatory Subunit 12A, PPP1R12A, Myosin Phosphate target subunit 1

**Cat. No.** 68-0045-100  
**Lot. No.** 30284

**Quantity:** 100 µg  
**Storage:** -20°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS

Page 2 of 2

## Background

Continued from page 1

807/811) and reducing E2F activity. Demethylation of MYPT1 has been shown to increase the ubiquitin proteasome pathway-dependent turnover of MYPT1. This study offers a novel cell cycle regulatory mechanism mediated by methylation/demethylation dynamics, and also reveals the significance of LSD1 overexpression in human carcinogenesis (Cho *et al.*, 2011).

### Antibody Production:

Anti-MYPT1 pSer554 (mouse) polyclonal antibody was raised in sheep against MYPT1 (residues 547-618 of mouse MYPT1; Ser554 phosphorylated). The antibodies were purified by the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU, University of Dundee, Dundee, U.K.) by affinity purification of the anti-MYPT1 pAbs from the sheep serum using a GST-tagged antigen-agarose column. Anti-MYPT1 pSer554 (mouse) pAb was sourced by Ubiquigent directly from the MRC-PPU.

### General References:

Cheng JC, Cheng HP, Tsai IC and Jiang MJ (2013) ROS-mediated downregulation of MYPT1 in smooth muscle cells: a potential mechanism for the aberrant contractility in atherosclerosis. *Lab Invest* **93**, 422-433.

Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, Yoshimatsu M, *et al.* (2011) Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. *Cancer Res* **71**, 655-660.

Grassie ME, Moffat LD, Walsh MP and MacDonald JA (2011) The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1delta. *Arch Biochem Biophys* **510**, 147-159.

Takahashi N, Ito M, Tanaka J, Nakano T, Kaibuchi K, Odai H, *et al.* (1997) Localization of the gene coding for myosin phosphatase, target subunit 1 (MYPT1) to human chromosome 12q15-q21. *Genomics* **44**, 150-152.



[www.ubiquigent.com](http://www.ubiquigent.com)  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

**International:** +1-617-245-0020  
**US Toll-Free:** 1-888-4E1E2E3 (1-888-431-3233)  
**Email:** [sales.support@ubiquigent.com](mailto:sales.support@ubiquigent.com)

### UK HQ and TECHNICAL SUPPORT

**International:** +44 (0) 1382 381147 (9AM-5PM UTC)  
**US/Canada:** +1-617-245-0020 (9AM-5PM UTC)  
**Email:** [tech.support@ubiquigent.com](mailto:tech.support@ubiquigent.com)

Email [services@ubiquigent.com](mailto:services@ubiquigent.com) for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

**Limited Terms of Use:** For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0